Powered by

Dana Farber Cancer Institute (DFCI, Harvard Medical School, Cambridge, US) Adopts Genomic Vision's Platform to Develop New Drugs in Oncology

Feb 13, 2020 - Business Wire
Mergers and Acquisitions

Regulatory News:

GENOMIC VISION (Paris:GV) (FR0011799907 - GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced that its proprietary molecular combing technology is now being established as routine experimental test at the Dana Farber Cancer Institute (DFCI). DFCI is one of the world-leading research organization in the area of cancer research and new therapy development. From now on, DFCI projects can...